Kenneson J, Papini C, Tang S, Huynh K, Zhang C, Jorgensen W
ACS Bio Med Chem Au. 2025; 5(1):215-226.
PMID: 39990941
PMC: 11843330.
DOI: 10.1021/acsbiomedchemau.4c00109.
Niu Y, Qin P, Lin P
Future Med Chem. 2025; 17(4):485-499.
PMID: 39935356
PMC: 11834456.
DOI: 10.1080/17568919.2025.2463319.
Lewandowski E, Zhang X, Tan H, Jaskolka-Brown A, Kohaal N, Frazier A
Nat Commun. 2025; 16(1):1266.
PMID: 39893201
PMC: 11787374.
DOI: 10.1038/s41467-025-56651-x.
Xiong L, Chen Q, Liu H
Medicine (Baltimore). 2024; 103(48):e40720.
PMID: 39612422
PMC: 11608737.
DOI: 10.1097/MD.0000000000040720.
Anton D, Camargo de Lima J, Dahmer B, Camini A, Goettert M, Timmers L
Inflammopharmacology. 2024; 32(5):3007-3035.
PMID: 39048773
DOI: 10.1007/s10787-024-01525-9.
Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.
Ghasemiyeh P, Mohammadi-Samani S
Virol J. 2024; 21(1):98.
PMID: 38671455
PMC: 11055380.
DOI: 10.1186/s12985-024-02370-6.
Discovery of Pyrano[2,3-]pyrazole Derivatives as Novel Potential Human Coronavirus Inhibitors: Design, Synthesis, In Silico, In Vitro, and ADME Studies.
Allayeh A, El-Boghdady A, Said M, Saleh M, Abdel-Aal M, Abouelenein M
Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399412
PMC: 10892497.
DOI: 10.3390/ph17020198.
Geospatial Disparities in Federal COVID-19 Test-to-Treat Program.
Smith E, Oakley E
Am J Prev Med. 2023; 64(5):761-764.
PMID: 37085247
PMC: 9977692.
DOI: 10.1016/j.amepre.2023.01.022.
Synthesis, molecular docking, and binding Gibbs free energy calculation of β-nitrostyrene derivatives: Potential inhibitors of SARS-CoV-2 3CL protease.
Jia Z, Lan X, Lu K, Meng X, Jing W, Jia S
J Mol Struct. 2023; 1284:135409.
PMID: 36993878
PMC: 10033154.
DOI: 10.1016/j.molstruc.2023.135409.
Projected COVID-19 Mortality Reduction From Paxlovid Rollout.
Khunte M, Kumar S, Salomon J, Bilinski A
JAMA Health Forum. 2023; 4(3):e230046.
PMID: 36930169
PMC: 10024200.
DOI: 10.1001/jamahealthforum.2023.0046.
Multi-ligand molecular docking, simulation, free energy calculations and wavelet analysis of the synergistic effects between natural compounds baicalein and cubebin for the inhibition of the main protease of SARS-CoV-2.
Li H, Komori A, Li M, Chen X, Yang A, Sun X
J Mol Liq. 2023; 374:121253.
PMID: 36694691
PMC: 9854241.
DOI: 10.1016/j.molliq.2023.121253.
Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, Men K
Signal Transduct Target Ther. 2022; 7(1):387.
PMID: 36464706
PMC: 9719906.
DOI: 10.1038/s41392-022-01249-8.
Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS-CoV-2.
Chen X, Li H, Song H, Wang J, Zhang X, Han P
J Extracell Vesicles. 2022; 11(12):e12288.
PMID: 36450704
PMC: 9712136.
DOI: 10.1002/jev2.12288.
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir.
Akinosoglou K, Schinas G, Gogos C
Viruses. 2022; 14(11).
PMID: 36423149
PMC: 9696049.
DOI: 10.3390/v14112540.
Managing nirmatrelvir/ritonavir during COVID-19: pharmacists' experiences from the Perak state of Malaysia.
Chang C, Ong S, Lim X, Chew L, Rajan P
J Pharm Policy Pract. 2022; 15(1):70.
PMID: 36274169
PMC: 9589596.
DOI: 10.1186/s40545-022-00469-1.
Network Pharmacology and Bioinformatics Analysis Identifies Potential Therapeutic Targets of Paxlovid Against LUAD/COVID-19.
Zhang W, Yang Z, Zhou F, Wei Y, Ma X
Front Endocrinol (Lausanne). 2022; 13:935906.
PMID: 36157452
PMC: 9493477.
DOI: 10.3389/fendo.2022.935906.
A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.
Xue S, Wang X, Wang L, Xu W, Xia S, Sun L
Cell Discov. 2022; 8(1):88.
PMID: 36075899
PMC: 9453727.
DOI: 10.1038/s41421-022-00455-6.
Natural inhibitors of SARS-CoV-2 main protease: structure based pharmacophore modeling, molecular docking and molecular dynamic simulation studies.
Halimi M, Bararpour P
J Mol Model. 2022; 28(9):279.
PMID: 36031629
PMC: 9420677.
DOI: 10.1007/s00894-022-05286-6.
